146 related articles for article (PubMed ID: 38583907)
41. Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.
Marmorino F; Prisciandaro M; Giordano M; Ortolan E; Crucitta S; Manca P; Antoniotti C; Valenti MM; Danesi R; Conca V; Mazzoli G; Boccaccino A; Carullo M; Martinetti A; Sottotetti E; Masi G; Sposito C; Zaffaroni N; Milione M; Fontanini G; Del Re M; Pietrantonio F; Cremolini C
JCO Precis Oncol; 2022 Nov; 6():e2200244. PubMed ID: 36356286
[TBL] [Abstract][Full Text] [Related]
42. Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence.
Pedersen SK; Symonds EL; Roy AC; Cornthwaite KJ; LaPointe LC; Young GP
Cancer Med; 2023 Jan; 12(2):1319-1329. PubMed ID: 35822405
[TBL] [Abstract][Full Text] [Related]
43. Combined Analysis of Disseminated Tumor Cells (DTCs) and Circulating Tumor DNA (ctDNA) in a Patient Suffering from Triple Negative Breast Cancer Revealed Elevated Risk.
Nel I; Herzog H; Aktas B
Front Biosci (Landmark Ed); 2022 Jun; 27(7):208. PubMed ID: 35866394
[TBL] [Abstract][Full Text] [Related]
44. Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer.
Malla M; Parikh AR
Hematol Oncol Clin North Am; 2022 Jun; 36(3):583-601. PubMed ID: 35577710
[TBL] [Abstract][Full Text] [Related]
45. ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?
Puccini A; Martelli V; Pastorino A; Sciallero S; Sobrero A
Curr Treat Options Oncol; 2023 Feb; 24(2):76-92. PubMed ID: 36656505
[TBL] [Abstract][Full Text] [Related]
46. The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer.
Xie H; Kim RD
Ann Surg Oncol; 2021 Mar; 28(3):1845-1858. PubMed ID: 32776184
[TBL] [Abstract][Full Text] [Related]
47. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
[TBL] [Abstract][Full Text] [Related]
48. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
[TBL] [Abstract][Full Text] [Related]
49. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
50. Prognostic and Predictive Biomarkers in Oligometastatic Disease.
Barnum KJ; Weiss SA
Cancer J; 2020; 26(2):100-107. PubMed ID: 32205533
[TBL] [Abstract][Full Text] [Related]
51. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.
Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH
J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194
[TBL] [Abstract][Full Text] [Related]
52. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
53. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
54. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
55. Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.
Lam M; Loree JM; Pereira AAL; Chun YS; Kopetz S
Curr Treat Options Oncol; 2018 Feb; 19(2):11. PubMed ID: 29488033
[TBL] [Abstract][Full Text] [Related]
56. Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis.
Chen Y; Mo S; Wu M; Li Y; Chen X; Peng J
Int J Colorectal Dis; 2022 May; 37(5):1021-1027. PubMed ID: 35384496
[TBL] [Abstract][Full Text] [Related]
57. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.
Symonds EL; Pedersen SK; Murray DH; Jedi M; Byrne SE; Rabbitt P; Baker RT; Bastin D; Young GP
Clin Epigenetics; 2018; 10():63. PubMed ID: 29796114
[TBL] [Abstract][Full Text] [Related]
58. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.
Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE;
J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266
[TBL] [Abstract][Full Text] [Related]
59. Clinical application of circulating tumour DNA in colorectal cancer.
Loft M; To YH; Gibbs P; Tie J
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):837-852. PubMed ID: 37499673
[TBL] [Abstract][Full Text] [Related]
60. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
